BIOMARK PROVIDES Financial Results FOR THE YEAR ENDED MARCH 31, 2022, and Recent Corporate Highlights
BIOMARK PROVIDES FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2022, AND RECENT CORPORATE HIGHLIGHTS Vancouver, British Columbia – (July 14, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and […]
Form 7 Monthly Progress Report – July 2022
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 August 2nd, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not […]
Press Release – BioMark Continues to Strengthen its Intellectual Property position With New Patent<br>and Trademark Use in Canada
BioMark Continues to Strengthen its Intellectual Property position With New Patent and Trademark Use in Canada Vancouver, British Columbia – (June 21st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and […]
BioTech Brothers Interview with Rashid Ahmed CEO BioMark Diagnostics
Press Release – BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY TECHNOLOGY
BIOMARK ANNOUNCES CLOSING OF $1,5 MILLION FINANCING ROUND TO ACCELERATE COMMERCIALIZATION OF ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British Columbia – (May 4th, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is […]
CSE Form 7 – Monthly Progress Report – BioMark Diagnostics Inc. – Mar 2022
FORM 7MONTHLY PROGRESS REPORT Name of Listed Issuer: BioMark Diagnostics Inc. _____ (the “Issuer”). Trading Symbol: BUX Number of Outstanding Listed Securities: 77,974,229 Date: April 4th, 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. […]
BIOMARK TO PRESENT new CANCER SCREENING DATA using the LDTD-MS/MS technique AT THE ANNUAL ASMS Conference on Mass Spectrometry
BIOMARK TO PRESENT NEW CANCER SCREENING DATA USING THE LDTD-MS/MS TECHNIQUE AT THE ANNUAL ASMS CONFERENCE ON MASS SPECTROMETRY Vancouver, British Columbia – (April 27, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased […]
BioMark Monthly Progress Report April 4 2022
FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. BUX 77,974,229 April 4th 2022 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation […]
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]
BIOMARK RECEIVES $825K GRANT TO DEVELOP ITS LIQUID BIOPSY ASSAY FOR LUNG CANCER SCREENING
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) received funding to develop an early-stage lung cancer screening assay using BioMark’s proprietary liquid biopsy platform. The total sponsored research grant is about […]
